GLP-1 Drugs Show Promise in Reducing Risk of Multiple Obesity-Linked Cancers

New research indicates that medications like Ozempic may lower the risk of developing ten specific cancers in people with type 2 diabetes.

The study analyzed data from 1.7 million U.S. patients over 15 years.
GLP-1 drugs were associated with a reduced risk for cancers such as esophageal, colorectal, and pancreatic.
No significant reduction in risk was observed for thyroid, stomach, or breast cancers.
The findings support the potential broader health benefits of GLP-1 drugs beyond diabetes and weight loss.
Further research is needed to confirm these results and explore additional potential applications.